My watch list  


SB649868 is an orexin receptor antagonist in development by GlaxoSmithKline. Currently in Phase 2 development, this drug for sleep disorders is one of two such compounds currently in development, the other being Actelion's ACT-078573.

GSK presentation

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "SB649868". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE